REPUBLIC OF SOUTH AFRICA OR
JAPAN. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF THE LAW OF
ENGLAND AND
WALES BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis from the European Medicines Agency Committee for Orphan Medicinal Products . The positive opinion issued by COMP will be …
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
The positive opinion issued by COMP will be sent to the European Commission, which is expected to grant the orphan designation within 30 days. Under orphan designation in the European Union (EU), Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity. European guidelines for Orphan Drug Designation are for diseases affecting not more than five in 10,000 people in the EU.
TRADING UPDATES: HSBC announces redemption of US dollar securities
Thu, 15th Apr 2021 19:37
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.
RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.
Thu, 15th Apr 2021 19:37
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.
RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.
Blue Star Capital PLC - investment company with a focus on esports, payments, technology and its applications within media and gaming - Says investee Dynasty eSports Pte Ltd achieved its first monthly profit on an operating basis in January. Says Dynasty expects to shortly conclude a round of fundraising in which it is